Retatrutide dosing schedule
Sample dosing schedule
Important: in clinical studies the dose was increased gradually from the lowest starting point; jumping to a high dose too soon is associated with pronounced and long-lasting adverse effects (mostly gastrointestinal). Many do not need to reach the maximum dose. This information is provided for reference only; the product is intended for laboratory research and not for use in humans or animals.
| Weeks | Weekly dose | Stage |
|---|---|---|
| Week 1–4 | 2.5 mg | Initial onboarding dose |
| Week 5–8 | 5 mg | Dose escalation (if needed) |
| Week 9–12 | 7.5 mg | Dose escalation (if needed) |
| Week 13–16 | 10 mg | Dose escalation (if needed) |
| Week 17–20 | 12.5 mg | Dose escalation (if needed) |
| Week 21+ | 15 mg | Maximum indicated dose |
About the compound
Retatrutide is a triple GLP-1, GIP and glucagon receptor agonist. Adding the glucagon component is associated in studies with increased energy expenditure.
The data is provided for reference only.